the short answer
Librela and Adequan are both FDA-approved, but they are not interchangeable. Librela is a monthly monoclonal antibody injection labeled for osteoarthritis pain. Adequan is a polysulfated glycosaminoglycan injection labeled for signs of non-infectious degenerative or traumatic arthritis, given twice weekly for up to four weeks. Their routes, schedules, evidence, and adverse-event profiles differ. Neither is a cure, and neither is proven safer than the other. The prescription and monitoring belong to your vet.
| Librela (bedinvetmab) | Adequan (PSGAG) | |
|---|---|---|
| Status | FDA-approved monoclonal antibody for canine osteoarthritis pain. | FDA-approved polysulfated glycosaminoglycan for canine arthritis signs. |
| What it is | An anti-nerve growth factor (NGF) antibody that interferes with pain signaling. | A polysulfated glycosaminoglycan (PSGAG); the exact mechanism in canine joints is not known. |
| Labeled use | Control of pain associated with osteoarthritis in dogs. | Control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. |
| Route | Subcutaneous injection, given by a veterinarian. | Intramuscular injection, under veterinary direction. |
| Schedule | Once monthly, ongoing while prescribed. | Twice weekly for up to four weeks, maximum eight injections on the label. |
| Dose basis | Weight-based; the clinic selects the vial size. | Weight-based: 2 mg/lb, or 0.02 mL/lb, per injection. |
| Evidence | FDA-labeled field studies; post-approval safety reporting. | Label cites a laboratory distribution study and a clinical field trial. |
| Labeled reactions | Urinary tract infection, bacterial skin infection, dermatitis, increased BUN; injection-site pain is possible. | Transient injection-site pain, transient diarrhea, and abnormal bleeding. |
| Post-approval reports | Neurological signs including ataxia, seizures, paresis, and paralysis; GI, urinary, and general signs; death or euthanasia reported. | Vomiting, anorexia, depression/lethargy, diarrhea; death reported in very rare cases. |
| Cost structure | Clinic-billed monthly injection; weight-based vial; ongoing visits. | Clinic-billed series; weight-based vial count; 5 mL vials; follow-up depends on the vet. |
scroll the table sideways to compare →
The verdict
These drugs are not alternatives in the usual sense. Librela is labeled for osteoarthritis pain and is given monthly by a vet. Adequan is labeled for signs of non-infectious degenerative or traumatic arthritis and is given as a short intramuscular series. One is not a substitute for the other, and neither is a cure. If your dog has arthritis, the choice — or the decision to use neither — belongs to your vet, based on the diagnosis, other conditions, and the monitoring plan.
What the labels actually say
Librela’s label is about pain: it is indicated for the control of pain associated with osteoarthritis in dogs, given subcutaneously once a month, with the dose based on weight. Adequan’s label is about arthritis signs: it is indicated for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints, given intramuscularly at 2 mg/lb twice weekly for up to four weeks, with a maximum of eight injections. The label also says the specific mechanism in canine joints is not known. Different indications and different endpoints mean a head-to-head potency comparison is not supported by the labels.
Evidence: different studies, different questions
Librela’s approval rests on FDA-reviewed field studies and a post-approval safety record; the label lists common study events and later reports. Adequan’s label cites a laboratory distribution study and a clinical field trial that reported improvement in range of motion and total orthopedic score versus saline. Those are not the same endpoints, and we found no head-to-head trial that would let us rank one over the other for every dog. “FDA-approved” means each product met the standard for its own labeled use, not that they are interchangeable.
Safety: known risks, not a ranking
Librela’s labeled study reactions include urinary tract infection, bacterial skin infection, dermatitis, and increased BUN; injection-site pain is possible. Post-approval reports include neurological signs such as ataxia, seizures, paresis, and paralysis, plus gastrointestinal, urinary, and general signs, and death or euthanasia has been reported as an outcome. Adequan’s labeled reactions include transient injection-site pain, transient diarrhea, and abnormal bleeding; post-approval reports include vomiting, anorexia, depression/lethargy, diarrhea, and very rare death. Adequan is contraindicated in dogs with known or suspected bleeding disorders or PSGAG hypersensitivity and should be used with caution in dogs with renal or hepatic impairment. These are different risk profiles. Less data does not mean a product is safer, and more reports do not prove a higher rate. Do not stop or change either prescription without your vet.
Cost structure: two different bills
There is no reliable national price for either drug, and we will not invent one. Librela is a clinic-administered monthly injection, so the bill can include the drug, the injection, the exam, and monitoring, month after month. Adequan is a clinic-billed series: the label dose is weight-based, the vial is 5 mL, and a large dog may need more than one vial for the four-week series. Ask for an itemized quote that covers the drug, administration, exam, follow-up, and any leftover or wasted drug, then compare the total for the first three and six months. The cheaper sticker is not always the cheaper plan.
Where each loses
Librela loses on convenience and commitment: it requires a monthly clinic visit, the cost continues while it is prescribed, and the post-approval neurological reports are serious enough that owners should know them. It is also not for every dog; Veterinary Partner lists age, breeding, and pregnancy restrictions. Adequan loses on schedule and scope: it is a series of intramuscular injections, the labeled course is limited to four weeks, injection-site pain and bleeding are labeled concerns, and the labeled evidence is tied to a different endpoint. Neither drug rebuilds a joint, reverses arthritis, or guarantees comfort. A research-use peptide is not a substitute for either FDA-approved drug.
Questions owners ask
Are Librela and Adequan the same type of drug?
No. Librela is a monoclonal antibody against nerve growth factor, labeled for osteoarthritis pain. Adequan is a polysulfated glycosaminoglycan, labeled for signs of non-infectious degenerative or traumatic arthritis. They have different routes, schedules, and labeled uses.
Can my dog get Librela and Adequan together?
Ask your vet. They are different prescription products, and there is no head-to-head evidence in the sources we reviewed to guide combination use. The decision, timing, and monitoring belong to your vet.
Which is safer, Librela or Adequan?
They have different risk profiles, and neither is risk-free. Librela’s post-approval reports include serious neurological signs; Adequan’s labeled risks include injection-site, bleeding, and gastrointestinal effects. More data is not the same as more risk, and less data is not the same as safer. Your vet should match the choice to your dog.
Which is cheaper?
There is no reliable national price for either. Librela is clinic-billed monthly; Adequan is clinic-billed as a weight-based series. Ask for an itemized quote for the first three and six months, including the drug, administration, exams, and monitoring. Do not compare a per-vial price with a per-month price.
Sources
Reviewed October 30, 2026. These are the sources we used for this comparison. Dollar figures are estimates from the named source, not quotes.
- FDA: Librela package insertFDA-approved labeling for bedinvetmab injection; labeled indication, monthly subcutaneous use, and adverse events.
- Adequan Canine package insertFDA-approved labeling for polysulfated glycosaminoglycan; labeled indication, weight-based intramuscular series, and adverse events.
- VIN Veterinary Partner: Bedinvetmab (Librela)Revised February 13, 2025. Once-monthly veterinary injection, weight-based dose, post-approval reactions, and use restrictions.